Glaucoma is the second most prevalent cause of blindness worldwide, and the only effective management is the lowering of intraocular pressure (IOP). Selective laser trabeculoplasty (SLT) has become an essential part of glaucoma management since its commercial release in 2001. It has been an improvement from the previous argon laser trabeculoplasty (ALT), by using 1% of the laser energy, reducing the amount of anterior segment inflammation and minimising the degree of mechanical injury to the trabecular meshwork. There is now a large volume of work that demonstrates SLT is equally effective as ALT and topical medication in lowering IOP. It is simple to perform, with a well described side-effect profile, and is long-lasting and repeatable. This review will summarise the current literature on SLT for each of these topics.

中文翻译：

---

选择性激光小梁成形术：综述

青光眼是全球第二大最常见的失明原因，唯一有效的治疗方法是降低眼压 (IOP)。选择性激光小梁成形术 (SLT) 自 2001 年商业发布以来，已成为青光眼管理的重要组成部分。它是对之前的氩激光小梁成形术 (ALT) 的改进，通过使用 1% 的激光能量，减少前节段炎症和最大限度地减少对小梁网的机械损伤程度。现在有大量工作证明 SLT 在降低 IOP 方面与 ALT 和局部用药同样有效。它易于执行，具有良好描述的副作用概况，并且持久且可重复。这篇综述将总结每个主题的当前 SLT 文献。